Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMMXNASDAQ:LPTXNASDAQ:NBRVNASDAQ:PEPG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMMXImmix Biopharma$2.23-0.4%$2.09$1.26▼$3.00$62.44M0.31155,533 shs125,917 shsLPTXLeap Therapeutics$0.31-18.0%$0.38$0.22▼$4.79$15.62M-0.221.06 million shs52.68 million shsNBRVNabriva Therapeutics$0.00$1.22▼$8.45$45.46M1.5329,344 shs348 shsPEPGPepGen$1.39-4.1%$1.48$0.88▼$19.30$47.44M1.3834,813 shs161,514 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMMXImmix Biopharma-0.45%-7.08%+12.06%+20.54%+9.31%LPTXLeap Therapeutics-18.68%-21.23%-15.25%-20.36%-83.91%NBRVNabriva Therapeutics0.00%0.00%0.00%0.00%+4,900.00%PEPGPepGen-4.14%-6.71%-4.79%-7.95%-91.85%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIMMXImmix Biopharma3.0471 of 5 stars3.53.00.00.02.13.30.6LPTXLeap Therapeutics1.9846 of 5 stars3.14.00.00.00.60.01.3NBRVNabriva TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APEPGPepGen2.6231 of 5 stars3.23.00.00.01.12.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMMXImmix Biopharma 3.00Buy$7.00213.90% UpsideLPTXLeap Therapeutics 2.25Hold$4.921,491.15% UpsideNBRVNabriva Therapeutics 0.00N/AN/AN/APEPGPepGen 2.33Hold$7.67451.56% UpsideCurrent Analyst Ratings BreakdownLatest LPTX, IMMX, PEPG, and NBRV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2025IMMXImmix BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.005/29/2025PEPGPepGenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $8.005/9/2025PEPGPepGenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $14.003/27/2025LPTXLeap TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMMXImmix BiopharmaN/AN/AN/AN/A$0.48 per shareN/ALPTXLeap TherapeuticsN/AN/AN/AN/A$0.91 per shareN/ANBRVNabriva Therapeutics$35.59M0.00N/AN/A$0.10 per share0.00PEPGPepGenN/AN/AN/AN/A$3.64 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMMXImmix Biopharma-$21.61M-$0.70N/AN/AN/AN/A-130.02%-86.33%8/11/2025 (Estimated)LPTXLeap Therapeutics-$67.56M-$1.70N/AN/AN/AN/A-162.15%-120.05%8/11/2025 (Estimated)NBRVNabriva Therapeutics-$57.19M-$19.20N/AN/AN/A-148.11%-365.53%-135.81%N/APEPGPepGen-$89.98M-$3.13N/AN/AN/AN/A-81.26%-63.65%8/6/2025 (Estimated)Latest LPTX, IMMX, PEPG, and NBRV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025LPTXLeap Therapeutics-$0.38-$0.37+$0.01-$0.37N/AN/A5/8/2025Q1 2025PEPGPepGen-$0.72-$0.92-$0.20-$0.92N/AN/A3/26/2025Q4 2024LPTXLeap Therapeutics-$0.39-$0.37+$0.02-$0.37N/AN/A3/24/2025Q4 2024IMMXImmix Biopharma-$0.25-$0.16+$0.09-$0.16N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMMXImmix BiopharmaN/AN/AN/AN/AN/ALPTXLeap TherapeuticsN/AN/AN/AN/AN/ANBRVNabriva TherapeuticsN/AN/AN/AN/AN/APEPGPepGenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMMXImmix BiopharmaN/A1.801.80LPTXLeap TherapeuticsN/A2.412.41NBRVNabriva Therapeutics0.120.850.52PEPGPepGenN/A4.954.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMMXImmix Biopharma11.26%LPTXLeap Therapeutics30.46%NBRVNabriva Therapeutics0.27%PEPGPepGen58.01%Insider OwnershipCompanyInsider OwnershipIMMXImmix Biopharma55.40%LPTXLeap Therapeutics7.50%NBRVNabriva Therapeutics1.63%PEPGPepGen4.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMMXImmix Biopharma927.88 million12.43 millionOptionableLPTXLeap Therapeutics4041.44 million38.33 millionOptionableNBRVNabriva Therapeutics7032.02 million31.49 millionNot OptionablePEPGPepGen3032.72 million31.22 millionNot OptionableLPTX, IMMX, PEPG, and NBRV HeadlinesRecent News About These CompaniesInvestors in PepGen Inc. Should Contact The Gross Law Firm Before August 8, 2025 to Discuss Your Rights – PEPGJune 23 at 4:00 PM | globenewswire.comThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 8, 2025 in PepGen Inc. Lawsuit - PEPGJune 23 at 9:00 AM | prnewswire.comPEPGEN INC. (NASDAQ: PEPG) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds PepGen Inc. Investors of Upcoming DeadlineJune 23 at 8:30 AM | globenewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers - PEPGJune 22 at 10:00 AM | prnewswire.comROSEN, NATIONAL INVESTOR COUNSEL, Encourages PepGen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PEPGJune 21 at 11:34 AM | globenewswire.comPEPG Investors Have Opportunity to Lead PepGen Inc. Securities Fraud LawsuitJune 20, 2025 | prnewswire.comFaruqi & Faruqi Reminds PepGen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 11, 2025 - PEPGJune 20, 2025 | prnewswire.comPepGen Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Class Action Lawsuit Against PEPGJune 20, 2025 | prnewswire.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 8, 2025 in PepGen Inc. Lawsuit - PEPGJune 20, 2025 | prnewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers – PEPGJune 19, 2025 | morningstar.comThe Gross Law Firm Notifies PepGen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - PEPGJune 19, 2025 | prnewswire.comSHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against PepGen Inc. (NASDAQ: PEPG)June 19, 2025 | globenewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain ...June 19, 2025 | bakersfield.comTOP RANKED ROSEN LAW FIRM Encourages PepGen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PEPGJune 18, 2025 | globenewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers – PEPGJune 18, 2025 | globenewswire.comPepGen Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before August 8, 2025 to Discuss Your Rights – PEPGJune 18, 2025 | globenewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers - PEPGJune 17, 2025 | prnewswire.comClass Action Filed Against PepGen Inc. (PEPG) Over Securities Violations - Contact Levi & Korsinsky TodayJune 17, 2025 | accessnewswire.comPEPG INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that PepGen Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!June 17, 2025 | accessnewswire.comPEPG LAWSUIT ALERT: Levi & Korsinsky Notifies PepGen Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineJune 17, 2025 | prnewswire.comPepGen (NASDAQ:PEPG) Given New $8.00 Price Target at HC WainwrightMay 30, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLPTX, IMMX, PEPG, and NBRV Company DescriptionsImmix Biopharma NASDAQ:IMMX$2.23 -0.01 (-0.45%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$2.17 -0.06 (-2.69%) As of 06/23/2025 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.Leap Therapeutics NASDAQ:LPTX$0.31 -0.07 (-18.04%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$0.30 -0.01 (-4.21%) As of 06/23/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.Nabriva Therapeutics NASDAQ:NBRVNabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.PepGen NASDAQ:PEPG$1.39 -0.06 (-4.14%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$1.37 -0.02 (-1.44%) As of 06/23/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
